PALISADE BIO, INC. Accretion Expense
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2023-03-22
- PALISADE BIO, INC. accretion expense for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- PALISADE BIO, INC. accretion expense for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- PALISADE BIO, INC. accretion expense for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- PALISADE BIO, INC. accretion expense for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- PALISADE BIO, INC. accretion expense for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- PALISADE BIO, INC. accretion expense for fiscal 2021 was $2.34M, a 1057.92% increase from fiscal 2020.
- PALISADE BIO, INC. accretion expense for fiscal 2020 was $202.00K.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $0.00 derived: sum of 2 quarters · filed 2023-03-22 | $0.00 derived: sum of 3 quarters · filed 2023-03-22 | $0.00 10-K · filed 2023-03-22 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | $5.00K derived: sum of 4 quarters · filed 2023-03-22 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $0.00 10-Q · filed 2022-08-15 | $5.00K derived: sum of 3 quarters · filed 2023-03-22 | $136.00K derived: sum of 4 quarters · filed 2023-03-22 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-13 | $5.00K derived: sum of 2 quarters · filed 2023-03-22 | $136.00K derived: sum of 3 quarters · filed 2023-03-22 | $749.00K derived: sum of 4 quarters · filed 2023-03-22 |
| 2021-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $136.00K derived: sum of 2 quarters · filed 2023-03-22 | $749.00K derived: sum of 3 quarters · filed 2023-03-22 | $2.34M 10-K · filed 2023-03-22 |
| 2021-09-30 | $131.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $744.00K derived: sum of 2 quarters · filed 2022-11-14 | $2.33M 10-Q · filed 2022-11-14 | $2.50M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $613.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $2.20M 10-Q · filed 2022-08-15 | $2.37M derived: sum of 3 quarters · filed 2022-08-15 | $2.39M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $1.59M 10-Q · filed 2022-05-13 | $1.76M derived: sum of 2 quarters · filed 2022-05-13 | $1.78M derived: sum of 3 quarters · filed 2022-05-13 | |
| 2020-12-31 | $170.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $190.00K derived: sum of 2 quarters · filed 2022-03-17 | $202.00K 10-K · filed 2022-03-17 | |
| 2020-09-30 | $20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $32.00K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $12.00K 10-Q · filed 2021-08-23 |